Company Overview

Liquidia Corporation is a U.S.-based biopharmaceutical company focused on the development, manufacturing, and commercialization of therapies for pulmonary hypertension and other cardiopulmonary diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on rare disease markets. Its core revenue and value drivers center on inhaled therapeutics developed using its proprietary particle engineering platform technology, designed to optimize drug delivery, efficacy, and manufacturing scalability.

The company’s principal product candidate is YUTREPIA, an inhaled dry-powder formulation of treprostinil intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also commercializes products and services through Liquidia PAH, LLC and maintains proprietary technology through its PRINT particle engineering platform. Founded in 2004 and later becoming a publicly traded company on Nasdaq under the ticker LQDA, Liquidia evolved from a platform-focused nanotechnology company into a commercial-stage biopharmaceutical business concentrated on pulmonary hypertension therapies and specialty drug delivery systems.

Business Operations

Liquidia’s operations are primarily organized around two areas: the development and commercialization of pulmonary hypertension therapies and the advancement of its proprietary PRINT technology platform. The company generates revenue through product commercialization activities, licensing arrangements, manufacturing collaborations, and historically through contract development activities related to particle engineering technologies. Its primary operating focus in recent years has shifted toward commercialization readiness and expansion of its pulmonary hypertension franchise.

The company’s proprietary PRINT technology enables precise control over particle size, shape, and composition for inhaled and injectable therapeutics. Liquidia has conducted operations primarily in the United States while also maintaining relationships with international manufacturing, supply chain, and research partners. Strategic collaborations have included licensing and settlement arrangements related to treprostinil intellectual property and manufacturing capabilities. Liquidia has also operated through subsidiaries including Liquidia Technologies, Inc. and Liquidia PAH, LLC, which support commercialization and development activities.

Strategic Position & Investments

Liquidia’s strategic direction has focused on establishing a differentiated position in the pulmonary hypertension market through dry-powder inhalation technology and lifecycle innovation around treprostinil-based therapies. A major component of the company’s strategy has involved advancing YUTREPIA through regulatory processes while pursuing intellectual property and commercialization positioning within the competitive PAH therapeutic landscape. The company has invested heavily in manufacturing scale-up, regulatory preparedness, and commercialization infrastructure to support potential long-term market penetration.

In addition to internal development efforts, Liquidia has pursued acquisitions and strategic transactions to strengthen its pulmonary hypertension portfolio. The acquisition of RareGen, LLC expanded the company’s commercial capabilities and patient-support infrastructure. Liquidia continues to position its PRINT technology for broader applications in inhaled therapeutics, vaccines, and sustained-release drug delivery. Public filings and investor materials indicate ongoing interest in leveraging the platform for additional therapeutic categories, although commercialization beyond pulmonary hypertension remains comparatively early-stage.

Geographic Footprint

Liquidia is headquartered in Morrisville, North Carolina, within the United States biotechnology corridor. The company’s primary commercial and operational footprint remains concentrated in the United States, particularly due to the regulatory and commercial focus on U.S. pulmonary hypertension markets. Its manufacturing, regulatory, and commercialization activities are principally aligned with the North American healthcare system and specialty pharmaceutical distribution networks.

Despite its domestic concentration, Liquidia maintains broader international relevance through intellectual property holdings, supplier relationships, and potential future licensing opportunities. The company’s technologies and patents have applicability across multiple global pharmaceutical markets, and certain operational partnerships involve international manufacturing or development participants. Publicly available information indicates that the company’s direct commercial presence outside the United States remains limited relative to larger multinational pharmaceutical firms.

Leadership & Governance

Liquidia’s leadership team combines experience in biotechnology commercialization, pulmonary disease therapeutics, pharmaceutical manufacturing, and corporate finance. The company’s governance structure reflects a focus on commercialization execution, regulatory strategy, and intellectual property management. Strategic communications from management have consistently emphasized expanding patient access to inhaled pulmonary hypertension therapies while leveraging proprietary particle engineering capabilities for differentiated drug development.

Key executives include:

• Roger Jeffs – Chief Executive Officer
• Michael Kaseta – Chief Financial Officer
• Rajeev Saggar – President and Head of Research & Development
• Jason Adair – Chief Business Officer
• Marlene Ladisayo – Chief Operating Officer
• Ramy Farid – Chairman of the Board

Leadership strategy has centered on advancing commercial-stage operations, protecting intellectual property assets, and establishing Liquidia as a differentiated participant in the pulmonary hypertension treatment market. Information regarding executive roles and governance structure is consistent across SEC filings, investor presentations, and company disclosures.